BSTG — Biostage Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeSmall CapMomentum Trap
- $81.27m
- $82.40m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -476.15% | ||
| Return on Equity | -13968.21% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biostage, Inc. is a clinical-stage biotechnology company that uses cell therapy to regenerate organs inside the human body to treat cancer, trauma and birth defects. The Company's Cellframe technology uses the patient’s own stem cells from a simple adipose/fat tissue biopsy, expanded and banked, and then seeded onto a scaffold that mimics the natural dimensions of the organ being regenerated. Its product candidates include Cellspan esophageal implants, Cellspan bronchial implants and Cellspan tracheal implants. It is focused on developing its Cellspan esophageal implant for the treatment of esophageal atresia. Its esophageal implant consists of a hollow, tubular scaffold consisting of thin fibers of plastic made in the shape of the esophagus. Its Cellspan bronchial implants enable the surgeon to preserve the lung and repair the bronchus after surgical resection without debilitating outcomes and complications.
Directors
- David Green CHM (57)
- Hong Yu PRE (46)
- Jason Jing Chen VCH
- Peter Pellegrino CFO (46)
- Harout DerSimonian CSO
- Ting Li DRC
- Herman Sanchez DRC
- James Shmerling DRC (63)
- Junli He IND (47)
- Thomas Robinson IND
- Last Annual
- December 31st, 2021
- Last Interim
- September 30th, 2022
- Incorporated
- May 3rd, 2012
- Public Since
- October 14th, 2013
- No. of Shareholders
- 155
- No. of Employees
- 6
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 11,643,751
- Address
- 84 October Hill Rd Ste 11, HOLLISTON, 01746-1371
- Web
- http://www.biostage.com/
- Phone
- +1 7742337300
- Auditors
- Wei, Wei & Co., LLP
Upcoming Events for BSTG
Q1 2023 Biostage Inc Earnings Release
Similar to BSTG
20/20 Genesystems
Pink Sheets on Nasdaq
Aamaxan Transport
Pink Sheets on Nasdaq
Accustem Sciences
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
What is the Biostage share price?
As of Today at 12:03 UTC, shares in Biostage are trading at $6.98. This share price information is delayed by 15 minutes.
How has the Biostage share price performed this year?
Shares in Biostage last closed at $6.98 and the price had moved by +118.13% over the past 365 days. In terms of relative price strength the Biostage share price has outperformed the S&P500 Index by +162.54% over the past year.
What are the analyst and broker recommendations for Biostage?
There is no consensus recommendation for this security.
What is the Biostage dividend yield?
Biostage does not currently pay a dividend.
Does Biostage pay a dividend?
Biostage does not currently pay a dividend.
When does Biostage next pay dividends?
Biostage does not currently pay a dividend.
How do I buy Biostage shares?
To buy shares in Biostage you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biostage?
As of the previous close price of $6.98, shares in Biostage had a market capitalisation of $81.27m.
Where are Biostage shares listed?
Here are the trading details for Biostage:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BSTG
What kind of share is Biostage?
Based on an overall assessment of its quality, value and momentum Biostage is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biostage share price forecast for 2022?
We could not find analyst target price data for this security.
What is the trend in the Biostage share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biostage. Over the past six months, its share price has outperformed the S&P500 Index by +49.56%.
As of the last closing price of $6.98, shares in Biostage were trading +33.99% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biostage PE Ratio?
The Biostage PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.98.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biostage?
Biostage's management team is headed by:
- David Green - CHM
- Hong Yu - PRE
- Jason Jing Chen - VCH
- Peter Pellegrino - CFO
- Harout DerSimonian - CSO
- Ting Li - DRC
- Herman Sanchez - DRC
- James Shmerling - DRC
- Junli He - IND
- Thomas Robinson - IND